A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in participants with Moderately to Severely Active Ulcerative Colitis

Clinical Studies - Feb 1, 2021 - Jan 1, 2024

Completed

Project leader: Brand Stephan
Members: Smolders Jolijn, Krieger-Grübel Claudia

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3

Clinical Studies - Jan 29, 2021 - Dec 1, 2024

Ongoing

Project leader: Brand Stephan
Members: Krieger-Grübel Claudia, Smolders Jolijn

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis

Clinical Studies - Oct 1, 2020 - Dec 1, 2022

Completed

Project leader: Brand Stephan, Smolders Jolijn

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

Clinical Studies - Jan 1, 2019 - Aug 1, 2020

Completed

Project leader: Sulz Michael
Members: Brand Stephan, Krieger-Grübel Claudia, Smolders Jolijn

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Clinical Studies - Jan 1, 2019 - Dec 1, 2022

Automatically Closed

Project leader: Brand Stephan
Members: Sulz Michael, Smolders Jolijn, Krieger-Grübel Claudia

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 1

Clinical Studies - Jan 1, 2018 - Feb 1, 2021

Completed

Project leader: Brand Stephan
Members: Krieger-Grübel Claudia, Sulz Michael, Smolders Jolijn

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

Clinical Studies - Jan 1, 2018 - Jun 1, 2021

Automatically Closed

Project leader: Brand Stephan
Members: Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn

A MULTICENTER, MULTI-NATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE IIA STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AN ANTHOCYANIN RICH EXTRACT (ACRE) IN PATIENTS WITH ULCERATIVE COLITIS.

Clinical Studies - Jan 1, 2018 - Jul 1, 2021

Completed

Project leader: Brand Stephan
Members: Stillhard Roman, Sulz Michael, Krieger-Grübel Claudia, Smolders Jolijn

A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis

Clinical Studies - Jan 1, 2017 - Dec 1, 2022

Automatically Closed

Project leader: Sulz Michael
Members: Smolders Jolijn, Brand Stephan

swiss eosinophil oesophagithis cohort

Fundamental Research - Jan 1, 2006 - Dec 31, 2030

Ongoing

Members: Brand Stephan, Sulz Michael, Smolders Jolijn